Cifras calculadas a partir de notificaciones regulatorias oficiales — .
Propiedadiniciados 0.03% · instituciones 1.21% · posiciones cortas 0.4% del flotante
En USD · a Oct 19, 2026
Pregúntale a la máquina
Busca y compara operaciones de iniciados, sociedades y sus estadísticas en lenguaje natural. Tu pregunta se convierte en una consulta sobre los datos disponibles, no en una conversación ni en asesoramiento de inversión.
Solo datos de Clearmind Medicine Inc.. Sin búsqueda web. Se excluyen las estadísticas globales de cada iniciado.
Una búsqueda ejecutada consume un crédito, incluso sin resultados. Los errores y las preguntas no compatibles no consumen créditos.
Clearmind Medicine Inc., a clinical stage pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. The company develops treatments for alcohol use disorders, binge drinking, and eating disorders, as well as weight loss, obesity, and metabolic syndrome, anxiety disorders, post-traumatic stress disorder, depression, and treatment resistant depression. It develops MEAI compound for the treatment of alcohol use disorder, obesity, and metabolic disorders, as well as an alcohol substitute consumer product; and CM-CMND-001 which is in Phase I/IIa clinical trial for the treatment of alcohol use disorder. In addition, the company has a strategic collaboration with SciSparc Ltd., Yissum Research Development Company of the Hebrew University of Jerusalem, Polyrizon Ltd., and NeuroThera Labs Inc. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
Fuente de información de mercado · Oct 19, 2026
Identidad según la SEC · Oct 19, 2026
Cronología en el mercado · historial completo
1 compra4 ventasbarra = volumen usd, escala √haz clic en un periodo para filtrar la tabla
| Iniciado | Tipo | Valor · USD | Señales | Detalle | |
|---|---|---|---|---|---|
| HRT FINANCIAL LPhistorial | Venta | $73.2K | SEC |
| HRT FINANCIAL LPhistorial | Venta | $10.6K | SEC |
| HRT FINANCIAL LPhistorial | Venta | $7.1K | SEC |
| HRT FINANCIAL LPhistorial | Compra | $330.3K | conv 52 | SEC |
| HRT FINANCIAL LPhistorial | Venta | $27.7K | SEC |